戻る Agenda
Pharma and Regulatory Perspectives on Machine Learning Applications in Pharmacovigilance
Session Chair(s)
Bruce Donzanti, PHD
PV Consultant
United States
Machine Learning is one approach in the fast-paced field of artificial intelligence that is positioned to address many key issues in pharmacovigilance. However, it presents several challenges which must be addressed by both industry and regulators. Join the Clinical Safety & Pharmacovigilance Community for a follow up Round Table discussion on Wednesday, June 26, 3:15-4:15PM in the DIA Community Zone 2, Sails Pavilion.
Learning Objective : Review updated developments in machine learning in PV; Discuss risks and challenges; Describe updates on regulatory landscape and areas of future development and collaboration.
Speaker(s)
Chapter Two: Implementing Automation, Machine Learning, and Analytics in Pharmacovigilance - Case Study
Lisa George, RPH
Eli Lilly and Company, United States
Advisor, Global Patient Safety, Case Management
FDA Perspective
Robert Ball, MD, MPH, MSC
FDA, United States
Deputy Director, Office of Surveillance and Epidemiology, CDER
MHRA Perspective
Mick Foy
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Director of Delivery